Literature DB >> 2905797

The treatment of tranquilizer dependence by propranolol.

C Hallström1, G Crouch, M Robson, P Shine.   

Abstract

Forty four subjects were treated for benzodiazepine dependence. The withdrawal programme lasted for 10 weeks and included regular group support sessions. Patients were also treated with either propranolol, placebo or "no pill" under double blind conditions. Twenty three patients complied with the full treatment regimen and completed the trial. The outcome of treatment was moderately successful, with 8 out of the 23 patients stopping their tranquilizers and a further 11 achieving a reduction of 50% or more of their original benzodiazepine dose. Tranquilizer dependence is a difficult condition to treat, but preliminary results suggest that propranolol is helpful in reducing the symptoms of benzodiazepine withdrawal.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905797

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

Review 1.  Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

2.  Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Authors:  John J Mariani; Robert J Malcolm; Agnieszka K Mamczur; Jean C Choi; Ronald Brady; Edward Nunes; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2016-03-10       Impact factor: 3.829

Review 3.  Control interventions in randomised trials among people with mental health disorders.

Authors:  Erlend Faltinsen; Adnan Todorovac; Laura Staxen Bruun; Asbjørn Hróbjartsson; Christian Gluud; Mickey T Kongerslev; Erik Simonsen; Ole Jakob Storebø
Journal:  Cochrane Database Syst Rev       Date:  2022-04-04

Review 4.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Withdrawing benzodiazepines in primary care.

Authors:  Malcolm Lader; Andre Tylee; John Donoghue
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

Review 7.  Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.

Authors:  Lone Baandrup; Bjørn H Ebdrup; Jesper Ø Rasmussen; Jane Lindschou; Christian Gluud; Birte Y Glenthøj
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15

8.  Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

Authors:  K Blum; M Gold; E J Modestino; D Baron; B Boyett; D Siwicki; L Lott; A Podesta; A K Roy; M Hauser; B W Downs; R D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2018-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.